12 results about "T-cell lymphoma" patented technology

The present disclosure relates generally to mutations in T cell lymphoma, and methods of use of the mutations in T cell therapy.

This invention relates to the field of biotechnology, specifically to compositions and their application in the preparation of drugs for the prevention and treatment of lymphoma. The invention provides a composition comprising clostridium tumefaciensin and epipitorone, which synergistically enhance the effects of targeting the LCP2-mediated IQGAP2 / LaminA / C / SUV39H1 axis to combat chemotherapy resistance in NK / T cell lymphoma. The combined use of these two drugs can significantly reverse chemotherapy resistance, providing a new treatment strategy and drug combination for relapsed / refractory NKTCL. Experimental comparisons of the efficacy of immunotherapy drugs such as PD-1 inhibitors revealed that the anti-cellular senescence drug combination of clostridium tumefaciensin and epipitorone provided by this invention is significantly more effective than PD-1 inhibitors.

The invention relates to application of a CD2 / 5 / 7 knockout anti-CD2 / 5 / 7 chimeric antigen receptor T cell to T cell lymphoma and leukemia. The present invention includes compositions and methods for treating T cell lymphoma and leukemia. In certain aspects, the compositions and methods include CAR T cells that target CD2, CD5, or CD7 and modified cells in which CD2, CD5, or CD7 has been knocked out.

The invention relates to a triple-effect T cell adapter for targeting T cell lymphoma TRBC1. The invention discloses a TRBC1-targeted triple-effect T cell adapter which is composed of an Fc region, a hinge region, a first Fab arm and a second Fab arm, and a third targeting module is covalently connected to the C end of the Fc region to form a Y-shaped triple-head antibody. The first Fab arm and the second Fab arm are respectively combined with TRBC1 and CD3, and the third Fab arm is combined with CD28 or CD137, so that three functions of tumor recognition, T cell recruitment and co-stimulation amplification are integrated. The two polypeptide chains are heterodimerized through CH3 region button mutation, and correct assembly is ensured. The structure supports module interchange, programmable regulation and control of synergistic signals, significantly enhances TRBC1 positive T cell lymphoma killing, reduces toxicity to normal T cells, has high activity and a wide safety window, and is suitable for preparation of related drugs.

The invention provides an anti-human CXCL13 rabbit monoclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of immune globulin, the anti-human CXCL13 rabbit monoclonal antibody can be specifically combined with CXCL13 protein, the specificity and sensitivity of immunodetection are remarkably improved, the anti-human CXCL13 rabbit monoclonal antibody is suitable for preparing an immunohistochemical detection kit, and the anti-human CXCL13 rabbit monoclonal antibody can be used for preparing immunohistochemical detection products. CXCL13 protein expression can be accurately detected, and a reliable tool is provided for diagnosis of diseases such as vascular immune maternal T cell lymphoma and peripheral T cell lymphoma.

The invention discloses a small molecule compound CBL0137 for treating skin T cell lymphoma and application of the small molecule compound CBL0137, and belongs to the technical field of biological medicine. The invention provides an application of a small molecule compound CBL0137 in preparation of a product for resisting skin T cell lymphoma. The invention discloses application of a small molecule compound CBL0137 in preparation of a product for improving sensitivity of skin T cell lymphoma cells to antitumor drugs. In-vitro cell experiments prove that CBL0137 can inhibit cell proliferation of skin T cell lymphoma, retard the cell cycle, promote cell apoptosis and induce pyroptosis, so that the anti-tumor effect is achieved; the anti-tumor effect of the CBL0137 in skin T cell lymphoma is verified, and the CBL0137 has important significance in improving the cure rate of CTCL patients and improving the life quality of the CTCL patients.

The application relates to application of a CaMKII-alpha inhibitor in preparation of a medicine for treating T cell lymphoma. The application can obviously down-regulate the expression level of CaMKII-alpha in T cell lymphoma through si-RNA, determines that CaMKII-alpha is a potential treatment target of T cell lymphoma, and identifies Evans blue as an effective CaMKII-alpha inhibitor through high-throughput screening. Experiments show that the Evans blue can obviously inhibit the growth of T cell lymphoma Jurkat cells and H9 cells, and the effect is similar to that of siRNA treatment. In-vivo experiments of Jurkat transplanted tumors also prove that the Evans blue realizes the in-vivo tumor inhibition effect by inhibiting CaMKII-alpha, and reveal a good tumor inhibition effect of the Evans blue on T cell lymphoma.

Provided herein are human cluster of differentiation 6 (CD6) binding molecules and nucleic acid sequences encoding such molecules. In particular embodiments, provided herein are human CD6 binding molecules (e.g., nanoantibodies) having first and optionally second single monomeric variable antibody domains (SMVAD) comprising certain CDRs, and methods of using such molecules in the treatment of T cell associated diseases (e.g., cancer, such as T cell lymphoma). In certain embodiments, the SMVAD comprises a camelidae animal, human, or humanized framework region.

The present disclosure relates generally to mutations in T cell lymphoma, and methods of use of the mutations in T cell therapy.

The invention relates to a novel organic arsine compound Z2-A-Z2 and an application of the novel organic arsine compound Z2-A-Z2 in tumor resistance. The organic arsine compound Z2-A-Z2 disclosed by the invention not only shows remarkable anti-DLBCL activity in an in-vitro experiment, but also can effectively induce tumor cell apoptosis; in an animal model, the compound also shows a good anti-tumor effect, has no obvious toxic or side effect and has an important clinical application value. As an epigenetic regulating agent, Z2-A-Z2 not only shows good anti-tumor activity to DLBCL, but also has the characteristics of low toxicity and high selectivity, and has clinical transformation potential. Besides, Z2-A-Z2 can also be applied to other malignant tumors (such as multiple myeloma and T cell lymphoma) depending on an epigenetic mechanism, or can be combined with existing targeted drugs and immunotherapy, so that the comprehensive curative effect of tumor treatment is improved.

Disclosed herein is a compound that has properties to treat a subject with T cell lymphoma as compared to conventional interferon. In addition, methods to use such compound to treat T-cell lymphoma are also disclosed.

This invention belongs to the field of bioinformatics technology and discloses a machine learning-based multi-omics molecular subtyping method for NK / T-cell lymphoma. The method includes: acquiring a multi-dimensional dataset of NK / T-cell lymphoma samples, which contains molecular feature data and corresponding four-category molecular subtype labels; iteratively partitioning the multi-dimensional dataset and training an XGBoost classifier using the partitioned datasets to obtain core classification features; the feature importance of the XGBoost classifier is represented by the average gain of the features across all partitions; using linear discriminant analysis to pre-evaluate the four-category discriminant potential of the core classification features; if the pre-evaluation result does not meet the target, the core classification features are reacquired; and based on the core classification features, training an XGBoost classification model using the multi-dimensional dataset to obtain a target classification model for NK / T-cell lymphoma molecular subtyping. This method enables accurate classification of NK / T-cell lymphoma four-category molecular subtypes.